



Vivimed

Date:30/05/2013

To

BSE Limited  
Listing Department  
P.J.Towers,Dalal Street,  
Mumbai – 400001

**BSE - Scripe Code : 532660**

Dear Sir/Madam

National Stock Exchange of India Ltd  
Listing Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra(E),Mumbai – 400051

**NSE- Symbol: VIVIMEDLAB**

**Sub: Outcome of the Meeting of the Board of Directors of the Company – reg**

The Board of Directors of the Company at its meeting held on May 30, 2013, inter alia, have approved the following :

1. Pursuant to clause 41 of Listing Agreement entered into with the stock exchange, considered and approved the submission of the Un audited Financial Results (Standalone & Consolidated) for the Quarter ended March 31,2013 and Audited financial results (Standalone& Consolidated) for the Year ended March 31,2013 attached herewith;
2. The Board took note of Auditor's Report on the Audited Financial Statements of the Company for the financial year ended March 31, 2013



**Vivimed**

3. The Board of Directors of the Company has recommended a dividend of Rs.3/- (30%) per equity share of Rs.10/- each for the financial year ended 31<sup>st</sup> March,2013 and the dividend if approved by share holders in ensuing annual general meeting, will be credited /despatched to those members entitled thereto as per record date/Book closure date to be decided subsequently.

An earnings related presentation including business highlights will be uploaded on the company's website [www.vivimedlabs.com](http://www.vivimedlabs.com)

You are requested to take note of the above.

Yours faithfully

For VIVIMED LABS LTD

**SANTOSH VARALWAR**  
**MANAGING DIRECTOR & CEO**



| Sl. No. | Particulars   | Quarter Ended             |                           |                           |                         | Year Ended              |  | INR in Lakhs |
|---------|---|---------------------------|---------------------------|---------------------------|-------------------------|-------------------------|--|--------------|
|         |   | 31.03.2013<br>(Unaudited) | 31.12.2012<br>(Unaudited) | 31.03.2012<br>(Unaudited) | 31.03.2013<br>(Audited) | 31.03.2012<br>(Audited) |  |              |
| 1       | <b>Income From Operations</b>   |                           |                           |                           |                         |                         |  |              |
|         | (a) Net Sales / Income from Operations (Net of Excise Duty)   | 10,824.98                 | 11,413.05                 | 9,110.58                  | 42,312.51               | 38,289.99               |  |              |
|         | (b) Other Operating Income  | 75.01                     | 68.43                     | 16.07                     | 337.93                  | 41.96                   |  |              |
|         | <b>Total Income From Operations (Net)</b>   | <b>10,899.98</b>          | <b>11,481.48</b>          | <b>9,126.64</b>           | <b>42,650.44</b>        | <b>38,331.95</b>        |  |              |
| 2       | <b>Expenses</b>   |                           |                           |                           |                         |                         |  |              |
|         | a. Cost of Raw Materials Consumed   | 5,749.37                  | 6,464.67                  | 4,752.53                  | 24,736.98               | 22,930.02               |  |              |
|         | b. Purchase of Stock in Trade   | -                         | -                         | -                         | -                       | -                       |  |              |
|         | c. Changes in Inventories of Finished Goods, Work-in-Progress and Stock in Trade                                  | 144.48                    | 484.36                    | 671.40                    | (755.32)                | (156.78)                |  |              |
|         | d. Employee Benefit Expenses  | 482.92                    | 311.96                    | 234.79                    | 1,550.85                | 1,057.86                |  |              |
|         | e. Depreciation and Amortisation Expenses   | 582.95                    | 385.00                    | 456.17                    | 1,720.68                | 1,055.10                |  |              |
|         | f. Other Expenditure  | 2,101.58                  | 1,779.31                  | 1,133.66                  | 7,415.35                | 6,058.23                |  |              |
|         | <b>Total Expenses</b>   | <b>9,061.30</b>           | <b>9,425.30</b>           | <b>7,248.56</b>           | <b>34,668.54</b>        | <b>30,944.43</b>        |  |              |
| 3       | <b>Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)</b>           | <b>1,838.68</b>           | <b>2,056.18</b>           | <b>1,878.08</b>           | <b>7,981.90</b>         | <b>7,387.52</b>         |  |              |
| 4       | <b>Other Income</b>   |                           |                           |                           |                         |                         |  |              |
| 5       | <b>Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)</b>                | <b>1,838.68</b>           | <b>2,056.18</b>           | <b>1,878.08</b>           | <b>7,981.90</b>         | <b>7,387.52</b>         |  |              |
| 6       | <b>Finance Costs</b>  | 480.87                    | 787.10                    | 450.48                    | 2,843.78                | 2,253.49                |  |              |
| 7       | <b>Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)</b>          | <b>1,357.81</b>           | <b>1,269.08</b>           | <b>1,427.60</b>           | <b>5,138.11</b>         | <b>5,134.02</b>         |  |              |
| 8       | <b>Exceptional Items</b>  |                           |                           |                           |                         |                         |  |              |
| 9       | <b>Profit / Loss from ordinary activities before Tax (7 - 8)</b>  | <b>1,357.81</b>           | <b>1,269.08</b>           | <b>1,427.60</b>           | <b>5,138.11</b>         | <b>5,134.02</b>         |  |              |
| 10      | <b>Tax Expenses</b>   | 471.72                    | 243.70                    | 350.99                    | 1,464.55                | 1,092.57                |  |              |
| 11      | <b>Net Profit / Loss from ordinary activities after Tax (9 - 10)</b>  | <b>886.09</b>             | <b>1,025.37</b>           | <b>1,076.61</b>           | <b>3,673.56</b>         | <b>4,041.46</b>         |  |              |
| 12      | <b>Extraordinary Items (net of tax expenses Rs. .... Lakhs)</b>   |                           |                           |                           |                         |                         |  |              |
| 13      | <b>Net Profit / Loss for period (11 - 12)</b>   | <b>886.09</b>             | <b>1,025.37</b>           | <b>1,076.61</b>           | <b>3,673.56</b>         | <b>4,041.46</b>         |  |              |
| 14      | <b>Share of Profit / (Loss) of associates</b>   |                           |                           |                           |                         |                         |  |              |
| 15      | <b>Minority Interest</b>  |                           |                           |                           |                         |                         |  |              |
| 16      | <b>Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)</b> | <b>886.09</b>             | <b>1,025.37</b>           | <b>1,076.61</b>           | <b>3,673.56</b>         | <b>4,041.46</b>         |  |              |
| 17      | <b>Paid up Equity Share Capital (Face value of Rs 10/- each)</b>  | 1,606.09                  | 1,393.39                  | 1,393.39                  | 1,606.09                | 1,393.39                |  |              |
| 18      | <b>Reserve excluding Regulation Reserves as per Balance Sheet of Previous Accounting Year</b>                     | 26,101.45                 | 26,101.45                 | 13,478.01                 | 26,101.45               | 13,478.01               |  |              |
| 19      | <b>Earnings per Share (before Extraordinary Items) (of Rs. ..../- each) (not annualised)</b>                      |                           |                           |                           |                         |                         |  |              |
|         | (a) Basic   | 5.52                      | 7.36                      | 7.73                      | 22.87                   | 29.00                   |  |              |
|         | (b) Diluted   | 5.52                      | 6.38                      | 6.70                      | 22.87                   | 25.16                   |  |              |

1. The above Standalone Unaudited Financial Results for the Quarter ended March 31, 2013 and Standalone audited financial results for the year ended March 31 2013 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on May 30 2013.

2. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website [www.vivimedlabs.com](http://www.vivimedlabs.com) and also on BSE & NSE websites.

3. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

4. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

Place : Hyderabad  
Date : 30.05.2013.

For VIVIMED LABS LIMITED  
(SANTOSH VAKALIMAR)  
MANAGING DIRECTOR & CEO



VIVIMED LABS LIMITED

SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING AGREEMENT

(INR in Lakhs)

| Particulars   | Quarter Ended    |                  |                  |                  | Year Ended       |  |
|---|------------------|------------------|------------------|------------------|------------------|--|
|   | 31.03.2013       | 31.12.2012       | 31.03.2012       | 31.03.2013       | 31.03.2012       |  |
|   | Unaudited        | Unaudited        | Unaudited        | Audited          | Audited          |  |
| <b>1. Segment Revenue</b><br>(net sales/income from each segment should be disclosed under this head) |                  |                  |                  |                  |                  |  |
| a. Speciality Chemicals Business  | 8,580.57         | 8,853.10         | 6,657.92         | 32,864.44        | 27,873.35        |  |
| b. Pharma Business  | 2,244.41         | 2,559.95         | 2,452.66         | 9,448.07         | 10,416.65        |  |
| <b>Total</b>  | <b>10,824.98</b> | <b>11,413.05</b> | <b>9,110.58</b>  | <b>42,312.51</b> | <b>38,289.99</b> |  |
| Less, Inter Segment Revenue   | -                | -                | -                | -                | -                |  |
| <b>Net sales / Income from Operations</b>   | <b>10,824.98</b> | <b>11,413.05</b> | <b>9,110.58</b>  | <b>42,312.51</b> | <b>38,289.99</b> |  |
| <b>2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment</b>           |                  |                  |                  |                  |                  |  |
| a. Speciality Chemicals Business  | 1,605.39         | 1,481.47         | 1,287.24         | 6,410.83         | 4,970.17         |  |
| b. Pharma Business  | 233.29           | 574.71           | 590.84           | 1,571.07         | 2,417.35         |  |
| <b>Total</b>  | <b>1,838.68</b>  | <b>2,056.18</b>  | <b>1,878.08</b>  | <b>7,981.90</b>  | <b>7,387.52</b>  |  |
| Less: 1. Interest   | 480.87           | 787.10           | 450.48           | 2,843.78         | 2,253.49         |  |
| 2. Other Un-allocable Expenditure   | -                | -                | -                | -                | -                |  |
| 3. Un-allocable Income  | -                | -                | -                | -                | -                |  |
| <b>Total Profit Before Tax</b>  | <b>1,357.82</b>  | <b>1,269.08</b>  | <b>1,427.60</b>  | <b>5,138.11</b>  | <b>5,134.03</b>  |  |
| <b>3. Capital Employed</b>  |                  |                  |                  |                  |                  |  |
| a. Speciality Chemicals Business  | 77,019.49        | 79,486.78        | 64,436.00        | 77,019.49        | 64,436.00        |  |
| b. Pharma Business  | 7,554.32         | 7,068.48         | 6,003.20         | 7,554.32         | 6,003.20         |  |
| <b>Total</b>  | <b>84,573.81</b> | <b>86,555.26</b> | <b>70,439.20</b> | <b>84,573.81</b> | <b>70,439.20</b> |  |

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)

MANAGING DIRECTOR & CEO

Place : Hyderabad

Date : 30.05.2013



**VIVIMED LABS LIMITED**  
**CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED MARCH 31, 2013**

INR in Lakhs

| Sl. No.   | Particulars   | Quarter Ended             |                           |                           | Year Ended              |                         |
|-----------|---|---------------------------|---------------------------|---------------------------|-------------------------|-------------------------|
|           |   | 31.03.2013<br>(Unaudited) | 31.12.2012<br>(Unaudited) | 31.03.2012<br>(Unaudited) | 31.03.2013<br>(Audited) | 31.03.2012<br>(Audited) |
| <b>1</b>  | <b>Income From Operations</b>   |                           |                           |                           |                         |                         |
|           | (a) Net Sales / Income from Operations (Net of Excise Duty)   | 29,807.04                 | 27,211.94                 | 25,106.01                 | 1,10,879.56             | 66,831.38               |
|           | (b) Other Operating Income  | (194.05)                  | 226.85                    | 90.02                     | 1,187.35                | 268.23                  |
|           | <b>Total Income From Operations (Net)</b>   | <b>29,612.99</b>          | <b>27,438.79</b>          | <b>25,196.03</b>          | <b>1,12,066.91</b>      | <b>67,099.61</b>        |
| <b>2</b>  | <b>Expenses</b>   |                           |                           |                           |                         |                         |
|           | a. Cost of Raw Materials Consumed   | 13,285.32                 | 13,990.81                 | 11,525.38                 | 53,743.28               | 35,573.68               |
|           | b. Purchase of Stock in Trade   | -                         | -                         | -                         | -                       | -                       |
|           | c. Changes in Inventories of Finished Goods, Work-in-Progress and Stock in Trade                                  | 81.06                     | (45.46)                   | 202.11                    | (2,415.90)              | (1,835.31)              |
|           | d. Employee Benefit Expenses  | 1,435.33                  | 932.73                    | 1,387.85                  | 5,032.73                | 3,422.45                |
|           | e. Depreciation and Amortisation Expenses   | 1,632.11                  | 1,429.18                  | 1,345.70                  | 5,881.08                | 2,678.94                |
|           | f. Other Expenditure  | 10,290.01                 | 8,845.77                  | 7,362.96                  | 35,944.97               | 16,640.79               |
|           | <b>Total Expenses</b>   | <b>26,723.83</b>          | <b>25,153.03</b>          | <b>21,824.00</b>          | <b>98,186.17</b>        | <b>56,480.55</b>        |
| <b>3</b>  | <b>Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)</b>           | <b>2,889.16</b>           | <b>2,285.76</b>           | <b>3,372.03</b>           | <b>13,880.74</b>        | <b>10,619.06</b>        |
| <b>4</b>  | <b>Other Income</b>   |                           |                           |                           |                         |                         |
| <b>5</b>  | <b>Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)</b>                | <b>2,889.16</b>           | <b>2,285.76</b>           | <b>3,372.03</b>           | <b>13,880.74</b>        | <b>10,619.06</b>        |
| <b>6</b>  | <b>Finance Costs</b>  |                           |                           |                           |                         |                         |
| <b>7</b>  | <b>Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)</b>          | <b>501.85</b>             | <b>984.19</b>             | <b>809.91</b>             | <b>4,093.18</b>         | <b>2,837.54</b>         |
| <b>8</b>  | <b>Exceptional items</b>  |                           |                           |                           |                         |                         |
| <b>9</b>  | <b>Profit / Loss from ordinary activities before Tax (7 - 8)</b>  | <b>2,387.30</b>           | <b>1,301.57</b>           | <b>2,562.12</b>           | <b>9,787.56</b>         | <b>7,781.52</b>         |
| <b>10</b> | <b>Tax Expenses</b>   |                           |                           |                           |                         |                         |
| <b>11</b> | <b>Net Profit / Loss from ordinary activities after Tax (9 - 10)</b>  | <b>888.40</b>             | <b>(391.28)</b>           | <b>332.53</b>             | <b>1,429.15</b>         | <b>1,467.84</b>         |
| <b>12</b> | <b>Extraordinary Items (net of tax expenses Rs. .... Lakhs)</b>   |                           |                           |                           |                         |                         |
| <b>13</b> | <b>Net Profit / Loss for period (11 - 12)</b>   | <b>1,498.90</b>           | <b>1,692.85</b>           | <b>2,229.60</b>           | <b>8,358.41</b>         | <b>6,313.68</b>         |
| <b>14</b> | <b>Share of Profit / (Loss) of associates</b>   |                           |                           |                           |                         |                         |
| <b>15</b> | <b>Minority Interest</b>  |                           |                           |                           |                         |                         |
| <b>16</b> | <b>Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)</b> | <b>1,498.90</b>           | <b>1,692.85</b>           | <b>2,229.60</b>           | <b>8,358.41</b>         | <b>6,313.68</b>         |
| <b>17</b> | <b>Paid up Equity Share Capital (Face value of Rs 10/- each)</b>  |                           |                           |                           |                         |                         |
| <b>18</b> | <b>Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year</b>                    | <b>1,606.09</b>           | <b>1,393.39</b>           | <b>1,393.39</b>           | <b>1,606.09</b>         | <b>1,393.39</b>         |
| <b>19</b> | <b>Earnings per Share (before Extraordinary Items) (of Rs. .... / - each) (not annualised)</b>                    |                           |                           |                           |                         |                         |
|           | (a) Basic   | 9.33                      | 12.15                     | 16.00                     | 52.04                   | 45.31                   |
|           | (b) Diluted   | 9.33                      | 10.54                     | 13.88                     | 52.04                   | 39.31                   |

- The above Consolidated Unaudited Financial Results for the Quarter ended March 31, 2013 & Consolidated results for the year ended Mar 31, 2013 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on May 30, 2013.
- Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz., (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Klar Schen Private Limited, (iv) Octantis Nobel Labs Private Limited, (v) Vivimed Holdings Limited and its step down subsidiary Vivimed Labs Europe limited (vi) Vivimed Labs Mauritius Limited and its step down subsidiaries viz., (a) Vivimed Labs UK Limited, (b) Vivimed Labs Spain, S.L. with its further step down subsidiaries namely (01) Union Quimico Farmaceutica S.A., Spain and (02) Holiday International Limited, UK with its further step down subsidiary Uniqifa Mexico S.A. de C.V.
- The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website [www.vivimedlabs.com](http://www.vivimedlabs.com) and also on BSE & NSE websites.
- As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
- Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

Place : Hyderabad  
 Date : 30.05.2013

For VIVIMED LABS LIMITED  
 (SANTOSH VARALWAR)  
 MANAGING-DIRECTOR & CEO



**VIVIMED LABS LIMITED**  
**SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING AGREEMENT**

(INR in Lakhs)

| Particulars   | Quarter Ended      |                    |                    | Year Ended         |                    |
|---|--------------------|--------------------|--------------------|--------------------|--------------------|
|   | 31.03.2013         | 31.12.2012         | 31.03.2012         | 31.03.2013         | 31.03.2012         |
|   | Unaudited          | Unaudited          | Unaudited          | Audited            | Audited            |
| <b>1. Segment Revenue</b><br>(Net Sales/Income from each segment should be disclosed under this head) |                    |                    |                    |                    |                    |
| a. Speciality Chemicals Business  | 10,286.68          | 9,552.25           | 8,092.76           | 37,038.67          | 33,626.26          |
| b. Pharma Business  | 19,520.36          | 17,659.69          | 17,013.25          | 73,840.89          | 33,205.12          |
| <b>Total</b>  | <b>29,807.04</b>   | <b>27,211.94</b>   | <b>25,106.01</b>   | <b>1,10,879.56</b> | <b>66,831.38</b>   |
| Less: Inter Segment Revenue   |                    |                    |                    |                    |                    |
| <b>Net sales / Income from Operations</b>   | <b>29,807.04</b>   | <b>27,211.94</b>   | <b>25,106.01</b>   | <b>1,10,879.56</b> | <b>66,831.38</b>   |
| <b>2. Segment Results(Profit)(+)/Loss(-) before tax and interest from each segment</b>                |                    |                    |                    |                    |                    |
| a. Speciality Chemicals Business  | 1,534.93           | 1,425.21           | 1,497.02           | 6,826.37           | 6,006.97           |
| b. Pharma Business  | 1,354.22           | 860.55             | 1,875.01           | 7,054.37           | 4,612.10           |
| <b>Total</b>  | <b>2,889.15</b>    | <b>2,285.76</b>    | <b>3,372.03</b>    | <b>13,880.74</b>   | <b>10,619.06</b>   |
| Less: 1. Interest   | 501.85             | 984.19             | 809.90             | 4,093.18           | 2,837.54           |
| 2. Other Un-allocable Expenditure net off   | -                  | -                  | -                  | -                  | -                  |
| 3. Un-allocable Income  | -                  | -                  | -                  | -                  | -                  |
| <b>Total Profit Before Tax</b>  | <b>2,387.30</b>    | <b>1,301.57</b>    | <b>2,562.13</b>    | <b>9,787.56</b>    | <b>7,781.52</b>    |
| <b>3. Capital Employed</b>  |                    |                    |                    |                    |                    |
| a. Speciality Chemicals Business  | 77,724.60          | 78,450.64          | 68,235.22          | 77,724.60          | 68,235.22          |
| b. Pharma Business  | 51,568.93          | 47,961.24          | 40,330.30          | 51,568.93          | 40,330.30          |
| <b>Total</b>  | <b>1,29,293.52</b> | <b>1,26,411.88</b> | <b>1,08,565.52</b> | <b>1,29,293.52</b> | <b>1,08,565.52</b> |

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
 MANAGING DIRECTOR & CEO

Place : Hyderabad  
 Date : 30.05.2013



| S.No       | Particulars                                | STANDALONE            |                       | CONSOLIDATED          |                       |
|------------|--|-----------------------|-----------------------|-----------------------|-----------------------|
|            |  | As at                 | As at                 | As at                 | As at                 |
|            |  | 31.03.2013<br>Audited | 31.03.2012<br>Audited | 31.03.2013<br>Audited | 31.03.2012<br>Audited |
| <b>(A)</b> | <b>EQUITY AND LIABILITIES</b>              |                       |                       |                       |                       |
| 1          | Shareholders funds                         |                       |                       |                       |                       |
|            | (a) Share Capital                          |                       |                       |                       |                       |
|            | i) Equity Share Capital                    | 1,606.09              | 1,393.39              | 1,606.09              | 1,393.40              |
|            | ii) Preference Share capital               | -                     | 6,700.00              | 6,394.56              | 13,094.60             |
|            | (b) Reserves and Surplus                   | 32,801.31             | 26,201.45             | 42,676.58             | 32,753.30             |
|            | (c) Money Received against Share Warrants  | 237.21                | 237.21                | 237.21                | 237.21                |
|            | <b>Sub Total Shareholders Funds</b>        | <b>34,644.61</b>      | <b>34,532.05</b>      | <b>50,914.44</b>      | <b>47,478.51</b>      |
| 2          | Share application money pending allotment  |                       |                       |                       |                       |
| 3          | <b>Minority interest *</b>                 |                       |                       |                       |                       |
| 4          | <b>Non-current liabilities</b>             |                       |                       |                       |                       |
|            | a) Long-term borrowings                    | 18,394.47             | 12,905.74             | 29,692.04             | 25,802.98             |
|            | (b) Deferred tax liabilities (net)         | 2,666.72              | 1,634.28              | 1,719.87              | 1,344.11              |
|            | (c) Other long-term liabilities            | 6,119.98              | 1,567.70              | 13,409.60             | 8,819.05              |
|            | (d) Long-term provisions                   | 197.23                | 180.90                | 146.67                | 106.81                |
|            | <b>Sub-total - Non-current liabilities</b> | <b>27,378.40</b>      | <b>16,288.62</b>      | <b>44,968.18</b>      | <b>36,072.95</b>      |
| 5          | <b>Current liabilities</b>                 |                       |                       |                       |                       |
|            | (a) Short-term borrowings                  | 22,562.63             | 20,255.36             | 30,112.73             | 23,282.29             |
|            | (b) Trade payables                         | 4,683.36              | 2,772.42              | 16,627.85             | 15,686.30             |
|            | (c) Other current liabilities              | 5,012.92              | 2,715.57              | 11,610.16             | 4,079.20              |
|            | (d) Short-term provisions                  | 1,197.41              | 1,184.41              | 2,722.30              | 3,321.10              |
|            | <b>Sub-total - Current liabilities</b>     | <b>33,456.32</b>      | <b>26,927.76</b>      | <b>61,073.04</b>      | <b>46,368.90</b>      |
|            | <b>TOTAL - EQUITY AND LIABILITIES</b>      | <b>95,479.34</b>      | <b>77,748.43</b>      | <b>1,56,955.66</b>    | <b>1,29,920.36</b>    |
| <b>(B)</b> | <b>ASSETS</b>                              |                       |                       |                       |                       |
| 1          | <b>Non-current assets</b>                  |                       |                       |                       |                       |
|            | (a) Fixed assets                           | 40,507.54             | 29,449.48             | 70,903.82             | 59,534.50             |
|            | (b) Capital Work In Progress               | 921.29                | 770.83                | 2,691.75              | 836.80                |
|            | (c) Non Current Investment                 | 9,554.55              | 8,716.93              | 24.35                 | 69.80                 |
|            | (d) Long Term Loans and advances           | -                     | -                     | -                     | -                     |
|            | (e) Other Non Current Assets               | 5.92                  | 3,006.13              | 1,827.06              | 4,765.49              |
|            | <b>Sub-total - Non-current assets</b>      | <b>50,989.30</b>      | <b>41,943.37</b>      | <b>75,446.98</b>      | <b>65,206.60</b>      |
| 2          | <b>Current Assets</b>                      |                       |                       |                       |                       |
|            | (b) Inventories                            | 14,035.86             | 7,388.21              | 34,026.28             | 24,787.79             |
|            | (c) Trade receivables                      | 16,005.97             | 9,871.75              | 30,822.50             | 22,160.78             |
|            | (d) Cash and cash equivalents              | 1,366.67              | 1,940.55              | 2,395.72              | 3,633.68              |
|            | (e) Short-term loans and advances          | 12,466.53             | 16,581.59             | 11,982.42             | 14,108.56             |
|            | (f) Other current assets                   | 615.01                | 22.95                 | 2,281.75              | 22.95                 |
|            | <b>Sub-total - Current assets</b>          | <b>44,490.03</b>      | <b>35,805.05</b>      | <b>81,508.68</b>      | <b>64,713.76</b>      |
|            | <b>TOTAL - ASSETS</b>                      | <b>95,479.34</b>      | <b>77,748.43</b>      | <b>1,56,955.66</b>    | <b>1,29,920.36</b>    |

Place : Hyderabad

Date : 30.05.2013



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
MANAGING DIRECTOR & CEO

VIVIMED LABS LIMITED

| Part II  |  |                          |                          |                          |                       |                       |
|--|--|--------------------------|--------------------------|--------------------------|-----------------------|-----------------------|
| Select Information for the Quarter and Year Ended 31/03/2013 |  |                          |                          |                          |                       |                       |
| SL.No  | Particulars  | Quarter ended 31/03/2013 | Quarter ended 31/03/2012 | Quarter ended 31/12/2012 | Year ended 31/03/2013 | Year ended 31/03/2012 |
| A  | <b>PARTICULARS OF SHAREHOLDING</b>   |                          |                          |                          |                       |                       |
|  | Public Shareholding  |                          |                          |                          |                       |                       |
|  | Number of Shares   | 9682136                  | 7642476                  | 7642776                  | 9682136               | 7642476               |
|  | Percentage of Shareholding   | 60.28%                   | 54.85%                   | 54.85%                   | 60.28%                | 54.85%                |
|  | Promoter and Promoter Group Shareholding   |                          |                          |                          |                       |                       |
|  | (a) Pledged/ Encumbered  |                          |                          |                          |                       |                       |
|  | Number of Shares   | <b>2252455</b>           | 1052455                  | 1577455                  | <b>2252455</b>        | 1052455               |
|  | Percentage of shares (as a % of the total shareholding of promoter and promoter group) | 35.31%                   | 16.73%                   | 25.07%                   | 35.31%                | 16.73%                |
|  | Percentage of shares (as a % of the total share capital of the company)                | 14.02%                   | 7.55%                    | 11.32%                   | 14.02%                | 7.55%                 |
|  | (b) Non-encumbered   |                          |                          |                          |                       |                       |
|  | Number of Shares   | 4126335                  | 5239011                  | 4713711                  | 4126335               | 5239011               |
|  | Percentage of shares (as a % of the total shareholding of promoter and promoter group) | 64.69%                   | 83.27%                   | 74.93%                   | 64.69%                | 83.27%                |
|  | Percentage of shares (as a % of the total share capital of the company)                | 39.72%                   | 45.15%                   | 45.15%                   | 39.72%                | 45.15%                |

**Investor's Complaints**

| Sl.no | Particulars                                    | 3 months ended 31/03/2013 |
|-------|--|---------------------------|
| B     | Pending at the beginning of the quarter        | Nil                       |
|       | Received during the quarter                    | 1                         |
|       | Disposed of during the quarter                 | 1                         |
|       | Remaining unresolved at the end of the quarter | Nil                       |

Place : Hyderabad  
Date : 30.05.2013



For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)  
MANAGING DIRECTOR & CEO